ZNF92 and breast cancer: These data indicate that the subset of poorly-differentiated high-grade breast cancers with elevated ZNF92 signature are almost two fold more likely to relapse compared to other high grade breast cancers with lower ZNF92 signature (HR = 1.9, p = 0.0006) (Supplementary Fig. 12).